Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REGROTON vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
250 mg orally twice daily
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Reserpine is extensively metabolized in the liver via hydrolysis and conjugation; chlorthalidone is metabolized minimally, mainly excreted unchanged in urine, with some hepatic conjugation.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Reserpine: 96% bound to albumin and alpha-1-acid glycoprotein; Chlorthalidone: 75% bound to erythrocytes (carbonic anhydrase) and 75% to plasma proteins (albumin)
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Reserpine: 2.5-3.5 L/kg; Chlorthalidone: 3-4 L/kg; clinical meaning: extensive tissue distribution with prolonged effect due to reserpine's irreversible binding to adrenergic neurons
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: reserpine 30-50%; chlorthalidone 64%
70-90% (oral); 100% (IV).
GFR 30-60 m L/min: use with caution; GFR <30 m L/min: contraindicated.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh Class A/B: reduce metoprolol dose by 50%; Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended for use in pediatric patients.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at half the standard dose (25 mg chlorthalidone/25 mg metoprolol) and titrate slowly due to increased risk of hypotension and electrolyte imbalance.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause depression, particularly in patients with history of depression; discontinue if signs appear.,Electrolyte imbalance (hypokalemia, hyponatremia) due to chlorthalidone.,Bradycardia and orthostatic hypotension.,Use cautiously in patients with renal impairment, gout, or diabetes.,Possible increased risk of breast cancer with long-term reserpine use.
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to reserpine, chlorthalidone, or sulfonamides (chlorthalidone is a sulfonamide).,Active peptic ulcer disease.,History of mental depression (especially with suicidal tendencies).,Anuria or severe renal impairment.,Electrolyte depletion (untreated hypokalemia, hypercalcemia).
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-potassium foods and salt substitutes (e.g., bananas, oranges, spinach, potassium-containing salt substitutes) due to risk of hyperkalemia with chlorthalidone. Limit alcohol intake. Maintain adequate hydration but avoid excessive fluid intake. Grapefruit juice may increase atenolol absorption; limit intake. Take with food to reduce GI upset.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiac anomalies, and oral clefts due to chlorthalidone; potential for fetal hypotension and oligohydramnios. Second and third trimesters: fetal hypotension, oligohydramnios, intrauterine growth restriction, and neonatal complications including electrolyte imbalances, thrombocytopenia, and jaundice. Avoid use in pregnancy, especially during second and third trimesters.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Chlorthalidone and reserpine are excreted into breast milk. Chlorthalidone M/P ratio not established; reserpine M/P ratio approximately 0.5. Use with caution due to potential for adverse effects in the nursing infant, including electrolyte disturbances and cardiac effects. Generally not recommended during breastfeeding.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No specific dose adjustments established. Due to increased plasma volume and renal clearance, efficacy may be reduced; however, risks generally outweigh benefits. Consider alternative antihypertensives. If used, start at lowest effective dose and monitor closely for electrolyte imbalances and hypotension.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
REGROTON is a fixed-dose combination of chlorthalidone (a thiazide-like diuretic) and atenolol (a cardioselective beta-blocker). Monitor for hypokalemia, hyperuricemia, and glucose intolerance from chlorthalidone. Atenolol may mask tachycardia in hypoglycemia and cause bradycardia; avoid abrupt discontinuation. Dosing adjustment needed in renal impairment (Cr Cl <30 m L/min contraindicated). Caution in COPD/asthma bronchospasm, peripheral vascular disease, and heart failure.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed, usually once daily, preferably in the morning to avoid nocturia.,Do not stop taking abruptly; sudden discontinuation may cause chest pain or palpitations.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or excessive thirst.,Check blood pressure and pulse regularly; keep a log.,Avoid alcohol, which can increase blood pressure lowering effects and cause dizziness.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Inform your doctor if you develop shortness of breath, wheezing, swelling, or unusual weight gain.,This drug may increase blood sugar; monitor glucose if diabetic.,Use sunscreen and protective clothing; medication can increase sun sensitivity.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REGROTON vs ALDOCLOR-250, answered by our medical review team.
REGROTON is a Antihypertensive Combination that works by Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REGROTON and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REGROTON is: 1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REGROTON and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REGROTON is classified as Category C. Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiac anomalies, and oral clefts due to chlorthalidone; potential for fetal hypotension and oligohyd. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.